{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    8,
    37,
    44,
    47,
    54,
    57,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schema Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "Schema",
        "description": "Reference to study schema in the synopsis summary"
      },
      {
        "id": "ref_2",
        "name": "Study Design Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Study Design",
        "description": "Reference to overall design regarding primary endpoint events"
      },
      {
        "id": "ref_3",
        "name": "Statistical Hypotheses Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.1",
        "sectionTitle": "Statistical Hypotheses",
        "description": "Reference to statistical power and event count"
      },
      {
        "id": "ref_4",
        "name": "Sample Size Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2",
        "sectionTitle": "Sample Size Determination",
        "description": "Reference to reduction in statistical power from 95% to 90%"
      },
      {
        "id": "ref_5",
        "name": "Analysis Populations Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.3",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference to definitions for primary endpoint populations"
      },
      {
        "id": "ref_6",
        "name": "Regulatory Oversight Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix A",
        "sectionTitle": "Regulatory, Ethical, and Study Oversight Considerations",
        "description": "Reference for informed consent details and study termination"
      },
      {
        "id": "ref_7",
        "name": "Hospitalization Definition Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix H",
        "sectionTitle": "Hospitalization Definition",
        "description": "Reference for guidance on defining COVID-19 hospitalization"
      },
      {
        "id": "ref_8",
        "name": "Contraceptive Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference for restricted contraceptive methods in Table 5"
      },
      {
        "id": "ref_9",
        "name": "Vaccination Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.5.1",
        "sectionTitle": "COVID-19 Vaccination",
        "description": "Reference for instructions on COVID vaccinations"
      },
      {
        "id": "ref_10",
        "name": "Liver Biochemistry Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix D",
        "sectionTitle": "Actions Required in Cases of Increases in Liver Biochemistry and Evaluation of Hyâ€™s Law",
        "description": "Reference for handling AST/ALT elevations"
      },
      {
        "id": "ref_11",
        "name": "SoA Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities for Cohort 1",
        "description": "Reference for injection site inspection timing"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "The potential impact of AZD7442 on COVID-19 vaccines is not known and has not been studied.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5 Summary of Permitted, Prohibited, or Restricted Medications",
        "pageNumber": 45
      },
      {
        "id": "annot_2",
        "text": "In case a participant shows an AST or ALT >= 3 x ULN together with TBL >= 2 x ULN please refer to Appendix D.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "8.2.4 Laboratory Assessments",
        "pageNumber": 55
      },
      {
        "id": "annot_3",
        "text": "Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of the study.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.1 Inclusion Criteria",
        "pageNumber": 38
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "7.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-06-30",
        "description": "Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442",
        "amendmentNumber": "Amendment 6"
      }
    ],
    "summary": {
      "referenceCount": 11,
      "annotationCount": 3,
      "versionCount": 1
    }
  }
}